Acorai has been selected as one of the five stand-out winners at the CHISEL Healthcare InnoMatch 2025 finals, earning a share of the S$3 million (USD 2.3 million) funding pool to pilot our innovative heart failure monitoring solution in real-world settings.
This global innovation challenge, organised by the Centre of Healthcare Innovation (CHI), presented by Temasek Foundation, and supported by the Ministry of Health Singapore (MOH), CHI Start-Up Enterprise Link (CHISEL) is a cross-cluster led platform that convenes the Singapore public healthcare system to accelerate the adoption of market solutions from start-ups and SMEs. It is an end-to-end process that matches market solutions to public healthcare needs and provides centralised funding and standardised evaluation to catalyse adoption.
For CHISEL Healthcare Innomatch 2025, Acorai is the only startup paired with two of Singapore’s three major public healthcare clusters – NHG Health and SingHealth. These partnerships will enable us to run real-world trials in these healthcare settings, validating our technology’s impact on early detection and management of heart failure
This can speed up the adoption of their digital health solutions, enabling patients to benefit from earlier access to quality and efficient care.
This year’s theme, “Building the Digital Health of the Future”, called for disruptive innovations to enhance patient access, care quality, and operational efficiency across hospital and community settings. Innovators are invited to reimagine care delivery through:
– AI-Enhanced Solutions: Clinical decision support, analytics, discharge planning, and transitional care.
– Smart Devices & Automation: Optimising manpower, reducing administrative processes, and enhancing care delivery.
– Digital Applications for Engagement: Tools for clinician support, personalised care plans, and remote monitoring.
Acorai’s solution aligns seamlessly with this vision, harnessing technology from the very start to redefine how care is delivered.
The winners of the CHISEL Healthcare InnoMatch 2025 are:
– 16 Bit (paired with NHG Health)
– Acorai (paired with NHG Health and SingHealth)
– AI Medical Services (paired with SingHealth)
– GyroGear (paired with NUHS)
– LIFESCAPES (paired with NUHS)
“Congratulations to the winners! Healthcare needs bold ideas that work! By catalysing test-beds and pairing innovators with our public clusters, we hope to generate timely evidence, de-risk adoption, and clear the path to scale, so patients see better access, better outcomes, and better value across Singapore’s healthcare system,” said Kee Kirk Chuen, Head, Health & Well-being, Temasek Foundation (TF).
Over 500 innovators online and in-person watched the InnoMatch finalists pitch their solutions before a powerhouse panel of judges, including representatives from Temasek Foundation, MOH Office for Healthcare Transformation, Synapxe, and one representative each from NHG Health, NUHS, and SingHealth.
Hosted by NHG Health through the Centre for Healthcare Innovation (CHI), this annual global challenge was launched in 2021 and is delivered under the CHI Start-up Enterprise Link (CHISEL) platform, presented by Temasek Foundation and supported by the Ministry of Health, Singapore (MOH).
Partnership with SLINGSHOT 2025
CHISEL Healthcare InnoMatch is a Partner Competition of SLINGSHOT, one of Asia’s leading global deep-tech start-ups pitching competitions organised by Enterprise Singapore. This partnership amplifies the reach and impact of CHISEL, providing winning teams with direct access to the region’s top innovation platforms.
At Acorai, this milestone underscores our mission to transform heart failure care globally. Stay tuned for updates on our Singapore pilots. We’re excited to share how we’re making cardiac monitoring smarter, simpler, and more accessible.
For more on CHISEL Healthcare InnoMatch, visit Temasek Foundation.
About Acorai
Acorai is dedicated to advancing non-invasive heart failure care by equipping clinicians with next-generation tools to improve patient outcomes. The company’s patented SAVE Sensor System is a pioneering multi-sensor platform designed to non-invasively estimate cardiac filling pressures, enabling more confident decision-making across the care continuum. Acorai has received FDA Breakthrough Device Designation and has studied its platform in over 2,000 patients. Supported by leading medtech investors and strategic partners, Acorai is committed to shaping the future of cardiac care through innovation in non-invasive monitoring.
For the latest updates, follow Acorai on LinkedIn or visit acorai.com
Media Contact
hello@acorai.com